In response to recent various market speculations regarding the future stock price of Elixiron Immunotherapeutics (Cayman) Limited (hereinafter as “Company”), the Company hereby issues the following statement to safeguard investor interests and maintain market information transparency:
1. Transparent Information Disclosure:
The Company, being an exempted company incorporated under the laws of the Cayman Islands and having not conducted any public offering within the jurisdiction of Taiwan, nevertheless consistently strictly adheres to the Securities and Exchange Act regulations. All information concerning revenue, profitability, and major operational decisions will be promptly announced in accordance with the requirements on the "Market Observation Post System" during the future public offering period. The Company hereby clarifies that any circulating rumors regarding the Company's future stock price trends or unverified performance forecasts are not information released by the Company.
2. Urging Investors to Exercise Prudent Judgment:
To protect the interests of shareholders and the investing public, the Company earnestly urges everyone to maintain a cautious attitude towards speculative information disseminated through social media, online forums, or unofficial channels. Investors are advised to base their judgments on the Company's fundamentals and refrain from readily believing unverified rumors to avoid compromising their own interests. For any questions or further information, please contact the Company directly.
3. Commitment to Creating Long-Term Value:
The Company's management team will continue to focus on the development of its core businesses, enhance operational efficiency, and dedicate efforts to creating long-term and stable investment value for shareholders.
Media Contact:
James Hsu, Vice President of Operations & Finance
ir@elixiron.com
+886 2 27827700
